Ultragenyx Pharmaceutical RARE Balance Sheet Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $421M+142% | $174M-18.7% | $214M+61.0% | $132.94M-56.8% | ||
| $259M-40.6% | $436M+19.9% | $363.63M-40.9% | $614.82M+42.1% | ||
| $158M+29.5% | $122M+66.2% | $73.39M+81.5% | $40.45M+42.3% | ||
| $52M+15.6% | $45M+32.5% | $33.97M+26.9% | $26.77M+64.9% | ||
| $951M+16.4% | $817M+11.6% | $732.18M-17.2% | $883.9M+3.2% | ||
| $244M-8.3% | $266M-8.5% | $290.57M+11.9% | $259.73M+83.9% | ||
| $44M0.0% | $44M-0.9% | $44.41M0.0% | $44.41M0.0% | ||
| $176M-1.1% | $178M+7.1% | $166.27M+3.9% | $160.11M+22.4% | ||
| $30M0.0% | $30M-0.2% | $30.06M-5.1% | $31.67M-4.9% | ||
| $60M-4.8% | $63M+9.2% | $57.69M+19.3% | $48.34M+135% | ||
| $57M-57.8% | $135M-32.5% | $199.9M+34.2% | $148.97M-42.5% | ||
| $1.53B+1.9% | $1.5B+0.8% | $1.49B-3.5% | $1.55B+1.5% | ||
| $19M+375% | $4M— | $0-100% | $204.68M+40.6% | ||
| $384M+11.6% | $344M+22.7% | $280.44M+7.4% | $261.21M+44.0% | ||
| $44M+159% | $17M+39.3% | $12.21M+153% | $4.82M+380% | ||
| $1.61B+29.3% | $1.24B+2.1% | $1.22B+1.9% | $1.19B+98.9% | ||
| $0— | $0— | $0— | $0— | ||
| $0— | $0-100% | $82K+17.1% | $70K+1.4% | ||
| $4.45B+5.6% | $4.21B+15.0% | $3.66B+16.6% | $3.14B+4.8% | ||
| -$4.53B-14.5% | -$3.96B-16.8% | -$3.39B-21.8% | -$2.78B-34.1% | ||
| $1M+200% | -$1M-255% | $647K+110% | -$6.57M-368% | ||
| $8M+100% | $4M+826% | $432K— | $0— | ||
| -$80M-131% | $255M-7.3% | $275M-21.9% | $352M-61.8% | ||
| $1.53B+1.9% | $1.5B+0.8% | $1.49B-3.5% | $1.55B+1.5% | ||
| $259M-40.6% | $436M+19.9% | $363.63M-40.9% | $614.82M+42.1% | ||
| $60M-4.8% | $63M+9.2% | $57.69M+19.3% | $48.34M+135% | ||
| $57M-57.8% | $135M-32.5% | $199.9M+34.2% | $148.97M-42.5% | ||
| $176M-1.1% | $178M+7.1% | $166.27M+3.9% | $160.11M+22.4% | ||
| $60M-4.8% | $63M+9.2% | $57.69M+19.3% | $48.34M+135% | ||
| $60M-4.8% | $63M+9.2% | $57.69M+19.3% | $48.34M+135% | ||
| $265M+10.0% | $241M+22.7% | $196.49M-4.0% | $204.68M+40.6% | ||
| $265M+10.0% | $241M+22.7% | $196.49M-4.0% | $204.68M+40.6% | ||
| $69M+38.0% | $50M+71.0% | $29.24M— | $0— | ||
| $19M+375% | $4M— | $0— | —— | ||
| $0— | $0-100% | $82K+17.1% | $70K+1.4% | ||
| $0— | $0— | $0— | $0— | ||
| $8M+100% | $4M+826% | $432K— | $0— | ||
| $30M0.0% | $30M-0.2% | $30.06M-5.1% | $31.67M-4.9% | ||
| $1.15B+39.9% | $820M-4.9% | $862.33M-1.5% | $875.44M+149% | ||
| $8M+100% | $4M+826% | $432K— | $0— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Can Ultragenyx Pharmaceutical cover its short-term obligations?
- Its current ratio is 2.02 — current assets exceed current liabilities.
- Where does Ultragenyx Pharmaceutical's balance sheet data come from?
- Every line is extracted from Ultragenyx Pharmaceutical's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.